BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues to maximize opportunities for its current portfolio and prepare for its upcoming oncology pipeline.

The US restructuring will streamline the company’s operations, enable it to best serve its current patients and maximize its contribution to the development of medicines that change the standard of care.

As part of the reorganization, the company will reduce headcount by around 280 employees from various locations in the USA.

"Our priorities are to bring spending in line with revenue, shift resources to maximize Injectafer and our abuse-deterrent pain treatments, and prepare for exciting potential new treatments for patients with cancer being developed by our R&D organization,” said Ken Keller, president, administrative and commercial at Daiichi Sankyo Inc.

“While the decision to reduce our workforce is a very difficult one, the changes are necessary to position us for long-term success. We are grateful for the contributions of all employees, and we are committed to making this process as easy and as streamlined as possible,” he added.